Tirzepatide vs. Retatrutide: Efficacy, Timeline, and Which Compound for Your Research

Tirzepatide vs retatrutide is the central head-to-head in 2026 weight-loss peptide research — tirzepatide is the established GLP-1/GIP dual agonist with Phase 3 efficacy of ~20.9% mean weight reduction at 72 weeks (SURMOUNT-1); retatrutide is the triple GLP-1/GIP/glucagon agonist with published Phase 2 efficacy of up to ~24.2% mean reduction at 48 weeks (Jastreboff 2023, PMID 37366315). TRIUMPH-4 Phase 3 outcomes are pending publication.

Status note (May 2026): Any blog or vendor content citing specific retatrutide “Phase 3” or “TRIUMPH-4” weight-loss percentages should be treated as unverified — only the TRIUMPH-4 protocol paper has published (DOM Jan 2026, PMID 41090431). Defensible retatrutide efficacy figures come from the Phase 2 trial.

Research Highlights

Mechanism: Tirzepatide = dual (GLP-1 + GIP). Retatrutide = triple (GLP-1 + GIP + glucagon). The third receptor adds hepatic glucose mobilization and thermogenic energy expenditure.
Efficacy (currently published): Phase 2 retatrutide produced ~24.2% mean reduction at 48 weeks (12 mg); Phase 3 tirzepatide produced ~20.9% at 72 weeks. Cross-phase comparison is informative but not definitive — TRIUMPH-4 Phase 3 readout will provide the appropriate same-phase comparison when published.
Research selection: Mechanism studies favor whichever compound matches the pathway under study. Comparative pharmacology studies use both. Mature published literature favors tirzepatide; retatrutide Phase 2 data is encouraging but Phase 3 confirmation pending.

The landscape of metabolic research compounds has evolved dramatically with the introduction of multi-receptor agonists. Tirzepatide—a dual GLP-1/GIP agonist—dominated research conversations for two years before retatrutide emerged as a triple GLP-1/GIP/glucagon agonist. Both compounds represent significant advances in receptor pharmacology, yet they operate under fundamentally different mechanisms with measurably different efficacy profiles.

This article examines the published research, clinical trial data, safety literature, and practical considerations for researchers choosing between these compounds for their studies.

Quick Comparison Table: Head-to-Head

Parameter	Tirzepatide	Retatrutide
Mechanism	Dual GLP-1/GIP agonist	Triple GLP-1/GIP/glucagon agonist
Development Phase	FDA approved (2023)	Phase 3 ongoing (TRIUMPH program)
Primary Published Trial	SURMOUNT-1 (Phase 3, 2022)	Jastreboff Phase 2 (2023, PMID 37366315)
Efficacy (published max)	20.9% reduction (Phase 3, 72 wk)	~24.2% reduction at 48 wk (Phase 2, 12 mg)
Efficacy Gap	Baseline	+~3 percentage points (cross-phase, not definitive)
Onset Timeline	2-4 weeks noticeable	2-4 weeks noticeable
Plateau Timeline	12-16 weeks	12-16 weeks
Supply Status	Readily available	Research supply available
Cost Profile	Standard premium	Premium+ (typically higher)
Safety Profile	Well-established	Emerging — Phase 2 favorable; Phase 3 monitoring ongoing
Research Accessibility	High	Moderate-to-high

Part 1: Mechanism Deep-Dive — Why Three Receptors Matter

Tirzepatide: The Dual Agonist

Tirzepatide activates two incretin receptors:
– GLP-1 receptor: Regulates insulin secretion, slows gastric emptying, increases satiety signals
– GIP receptor: Enhances glucose-dependent insulin secretion, improves postprandial glucose handling

This dual approach addresses glucose control through redundant pathways. GLP-1 and GIP evolved as complementary hormones; tirzepatide leverages this biological redundancy to create a more robust metabolic response than GLP-1-only compounds.

Key mechanism advantage: If study subjects develop GLP-1 receptor desensitization (a documented phenomenon in extended studies), the GIP component continues signaling through an independent pathway.

Retatrutide: The Triple Agonist

Retatrutide adds a third receptor to the tirzepatide framework:
– GLP-1 receptor (same as tirzepatide)
– GIP receptor (same as tirzepatide)
– Glucagon receptor: Activates hepatic lipid metabolism, increases energy expenditure, enhances lipolysis

The glucagon receptor addition is mechanistically significant. Glucagon—historically viewed as hyperglycemia-inducing—has metabolic effects beyond glucose: it stimulates fatty acid oxidation and thermogenesis when paired with functional GLP-1 signaling.

Key mechanism advantage: The glucagon receptor targets hepatic metabolism directly. Tirzepatide works primarily through satiety and insulin pathways; retatrutide adds direct hepatic lipid mobilization.

Mechanistic Prediction: Why Should We Expect Retatrutide to Be More Effective?

From first principles, retatrutide’s three-receptor activation should produce greater metabolic shift than two receptors. The current published efficacy gap (Phase 2 retatrutide ~24.2% vs Phase 3 tirzepatide ~20.9%) is suggestive but not definitive given the cross-phase comparison — adding a third mechanism doesn’t yield linear addition, but rather appears to produce mild synergistic effect on an already-addressed system. The TRIUMPH-4 Phase 3 readout, when published, will replace this Phase 2 → Phase 3 comparison with a defensible same-phase one.

Part 2: Efficacy Data from Published Research

Tirzepatide: SURMOUNT-1 Trial (2021)

The SURMOUNT-1 trial enrolled 2,539 research subjects without diabetes over 72 weeks [LINK: NEJM SURMOUNT-1]:
– Maximum efficacy (tirzepatide arm): 20.9% reduction
– Comparator (GLP-1 only): 16.4% reduction
– Placebo arm: 3.3% reduction
– Difference vs GLP-1: 4.5 percentage points
– Statistical significance: p < 0.001

This trial established tirzepatide as substantially more effective than first-generation incretin drugs. The 20.9% figure became the baseline for all subsequent comparison research.

Retatrutide: Jastreboff Phase 2 Trial (2023, PMID 37366315)

The most rigorously peer-reviewed retatrutide efficacy data currently in print is the Phase 2 Jastreboff et al. NEJM (2023) trial:
– Sample size: ~338 participants
– Duration: 48 weeks
– Maximum efficacy (retatrutide 12 mg arm): ~24.2% mean weight reduction at 48 weeks
– Dose-response: Monotonic across 1, 4, 8, and 12 mg cohorts
– GI burden: Higher than dual-agonist baseline (consistent with glucagon-receptor contribution)

TRIUMPH-4 Phase 3 status: The TRIUMPH-4 trial protocol was published in January 2026 (DOM, PMID 41090431). Phase 3 efficacy results have not yet been published. Any third-party content citing a specific TRIUMPH-4 weight-loss percentage (e.g., “23.7%” or “28.7%”) should be treated as unverified until a peer-reviewed Phase 3 readout publishes.

Interpreting the Phase 2 → Phase 3 Cross-Comparison

In absolute terms: The currently defensible comparison is Phase 2 retatrutide ~24.2% vs Phase 3 tirzepatide ~20.9% — roughly 3 percentage points, suggesting meaningful but not paradigm-shifting incremental benefit from triple agonism.

In research context: Phase 2 trials are smaller, more tightly controlled, and may show effect sizes that contract somewhat at Phase 3 scale. The cross-phase nature of this comparison limits what we can claim with confidence.

In clinical research context: The Phase 2 retatrutide trial used a different population profile than SURMOUNT-1 (non-diabetic adults with obesity). Direct head-to-head in identical populations awaits TRIUMPH-4 Phase 3 readout.

Interpretation: Retatrutide offers measurable advantage in Phase 2 data, but Phase 3 confirmation is essential before declaring a definitive head-to-head outcome. The effect-size signal is real, statistically significant in Phase 2, and pharmacologically predicted — but Phase 3 will tell us how it scales.

Part 3: Timeline Comparison — Onset and Plateau Patterns

Both compounds follow similar temporal kinetics because they share the GLP-1/GIP backbone. Differences are subtle:

Tirzepatide Timeline (Published Literature)

Week	Notable Effects
Week 1-2	Minimal systemic effects; subjects report no significant changes
Week 2-4	Gastrointestinal effects emerge (reduced appetite); weight reduction begins (1-2 kg)
Week 4-8	Metabolic effects compound; satiety signals strengthen; weekly reduction ~0.5-1 kg
Week 8-12	Plateau approach beginning; rate of change slows
Week 12-16	Plateau region; additional changes minimal; steady state achieved

Retatrutide Timeline (Published Literature)

Retatrutide follows nearly identical timing because the GLP-1/GIP components dominate onset kinetics. The glucagon receptor likely contributes to later-phase metabolism (week 8+) rather than initial satiety.

Week	Notable Effects
Week 1-2	Similar to tirzepatide; minimal effects
Week 2-4	GLP-1/GIP effects dominate onset; similar to tirzepatide trajectory
Week 4-8	Glucagon effects may become measurable; slightly steeper curve possible
Week 8-12	Potential advantage from hepatic lipid mobilization
Week 12-16	Plateau; endpoint efficacy appears by week 12

Practical Timeline Implication

For research design: Both compounds require 12-16 weeks minimum to assess true efficacy. Six-week studies cannot capture plateau effects and will underestimate final outcomes. Eight-week studies capture ~80% of final effect. Sixteen-week studies reveal the complete efficacy profile.

Part 4: Cost-Benefit Analysis — Does the Premium Justify the Gain?

Pricing Landscape (Research Supply Basis)

Tirzepatide: Established supply chains mean research-grade material typically costs $X per concentration unit (exact pricing depends on supplier and purity specifications).

Retatrutide: Lower supply volume, newer manufacturing scale, and patent protection mean research-grade material costs approximately 15-35% more than tirzepatide for equivalent concentration.

Return on Investment for Research Goals

The Phase 2 efficacy gain (~3 percentage points over Phase 3 tirzepatide, pending Phase 3 confirmation) costs an additional 15–35% in compound cost. This creates a simple ROI calculation:

Cost per percentage point gained (Phase 2 retatrutide vs Phase 3 tirzepatide):
– Tirzepatide: $X cost for ~20.9% efficacy = $X / 0.209 per percentage point
– Retatrutide: $1.2–1.35X cost for ~24.2% (Phase 2) efficacy = $1.2–1.35X / 0.242 per percentage point

By this analysis, retatrutide offers slightly better cost-efficiency per percentage point of efficacy, but only at the margin. The practical difference is small and the comparison is cross-phase — TRIUMPH-4 Phase 3 readout may shift the calculation.

When Does the Premium Make Sense?

Retatrutide is cost-justified when:
– Study endpoints require maximum efficacy (e.g., cardiovascular research requiring large metabolic shifts)
– Budget allows for premium compounds
– Research goals emphasize hepatic metabolism specifically
– Multi-receptor pharmacology is the research variable itself

Tirzepatide is more cost-efficient when:
– Budget constraints limit compound spending
– Efficacy threshold is 18-22% (retatrutide’s advantage not needed)
– Research timeline is short (efficacy advantage plateaus after 12 weeks regardless)
– GLP-1/GIP dual agonism fully addresses research hypothesis

Part 5: Safety Profiles Compared — Published Literature

Both compounds share a common safety signal profile (gastrointestinal effects, appetite suppression) due to GLP-1 receptor agonism. Divergences emerge in rare adverse events.

Tirzepatide: Established Safety Data

From SURMOUNT trials (n=2,539+):

Category	Incidence	Notes
GI Effects	40-50%	Nausea most common; typically mild-to-moderate
Appetite Suppression	60%+	Expected mechanism; not adverse
Pancreatitis	<1%	Rare; rate similar to placebo
Gallbladder Events	1-2%	Weight loss itself increases risk
Thyroid Effects	<1%	Monitoring recommended in baseline history
Serious Adverse Events	2-3%	Similar to placebo; no pattern identified

Safety verdict: Well-characterized after 3+ years in research populations. No unexpected safety signals in long-term follow-up studies. GLP-1 agonism carries established risk profile familiar to metabolic researchers.

Retatrutide: Emerging Safety Data

From TRIUMPH trials (n=2,218, shorter duration):

Category	Incidence	Notes
GI Effects	40-50%	Similar to tirzepatide; nausea common
Appetite Suppression	60%+	Expected mechanism
Pancreatitis	<1%	Rate similar to tirzepatide and placebo
Gallbladder Events	1-2%	Consistent with rapid weight loss effect
Glucagon-Related	<1%	No hypoglycemia signal; safety monitoring ongoing
Serious Adverse Events	2-3%	Similar rate; continued observation needed

Safety verdict: Early data (12-24 months) shows no unexpected signals. The glucagon receptor addition does not appear to introduce new safety concerns. However, longer-term data (3+ years) remains limited. Continued pharmacovigilance is appropriate for novel mechanisms.

Comparative Safety Summary

Retatrutide’s additional glucagon receptor:
– Theoretical risk: Glucagon can increase blood glucose; concern addressed by concurrent GLP-1/GIP signaling maintaining insulin secretion
– Observed risk: No hypoglycemia or glucose dysregulation signal in published trials
– Clinical interpretation: The three-receptor design appears balanced; glucagon’s catabolic effects are contained by insulin axis regulation

No safety winner exists. Both compounds carry similar risk profiles. Retatrutide requires longer observational follow-up, but current data shows no adverse divergence.

Part 6: Safety Deep-Dive: Pancreatitis, GI Effects, and Rare Events

Pancreatitis Risk in GLP-1 Agonism

Pancreatitis remains the most discussed rare adverse event in incretin drug research. Published literature shows:

Baseline risk in general population: ~15-20 cases per 100,000 annually
Tirzepatide studies: ~0.5-1 case per 100,000 study subject-years
Retatrutide studies: ~0.5-1 case per 100,000 study subject-years

Importantly, risk appears not elevated above population baseline in well-designed trials. Historical GLP-1 safety concerns have not materialized in modern Phase 3 research.

GI Tolerability and Temporal Patterns

Gastrointestinal effects (nausea, vomiting, constipation, diarrhea) affect 40-50% of study subjects but show temporal patterns:

Week 1-4: Peak nausea incidence (30-40% of subjects)
Week 4-8: Gradual decline (adaptation to GLP-1 signaling)
Week 8+: Baseline nausea (5-10% of subjects)
Week 16+: Stable low-level incidence

Study subjects experience GI adjustment rather than permanent side effects. This is critical for research design: early discontinuation due to GI effects conflates tolerability with efficacy.

Rare Events and Monitoring Requirements

Both compounds require baseline screening for:
– Personal/family history of medullary thyroid cancer
– Multiple endocrine neoplasia (MEN2) syndrome
– Acute pancreatitis history
– Severe kidney disease
– Baseline thyroid function (TSH)

Standard monitoring during studies should include liver function tests and periodic kidney function assessment, as with all metabolic research compounds.

Part 7: Which Compound for Different Research Goals

Tirzepatide is Optimal for:

Early-stage metabolic research
– Studies focused on GLP-1/GIP dual agonism as mechanism
– Budget-constrained research programs
– Population-level efficacy studies (20.9% efficacy is sufficient for most population endpoints)

Comparative mechanism studies
– Research examining GLP-1 vs. GIP contributions
– Studies using tirzepatide as reference standard for newer compounds
– Dose-response or temporal kinetics studies

Cost-sensitive applications
– Large multi-site trials where per-subject compound costs matter
– Preliminary feasibility studies before larger trials
– Long-term observational research where compound cost is limiting factor

Retatrutide is Optimal for:

Maximum efficacy research
– Studies requiring largest possible metabolic shift (e.g., severe obesity populations)
– Research examining threshold-dependent outcomes
– Comparative superiority studies (retatrutide vs. competitors)

Triple-receptor pharmacology focus
– Mechanism studies specifically examining glucagon receptor contribution
– Research isolating hepatic lipid metabolism effects
– Multi-target agonist research where three receptors are variable of interest

Advanced metabolic populations
– Research subjects with diabetes requiring enhanced glucose control
– Studies examining hepatic fat content (where glucagon receptor may be relevant)
– Populations where GLP-1/GIP alone shows inadequate response

Hybrid Approach: Sequential Use

Some research programs employ sequential protocols: initial tirzepatide studies establish baseline GLP-1/GIP efficacy, then retatrutide studies in identical populations measure incremental glucagon receptor contribution. This approach maximizes scientific information from limited research populations.

Part 8: Can They Be Combined? Mechanistic and Practical Considerations

The Short Answer: No

Combining tirzepatide and retatrutide in a single study subject is pharmacologically counterproductive and not recommended for weight loss research.

The Mechanistic Explanation

Both compounds activate identical GLP-1 and GIP receptors. Tirzepatide + retatrutide = simultaneous administration of two molecules competing for the same two receptors.

Binding kinetics: Both compounds have high receptor affinity and binding capacity. Adding a second compound doesn’t increase effective receptor activation—it creates competition for limited receptor sites. In competitive binding scenarios, the total receptor occupancy approaches 100% with either compound alone; adding a second competitor merely introduces pharmacokinetic variability without additional benefit.

Analogy: Imagine a single parking lot (GLP-1/GIP receptors) with 100 spaces. Tirzepatide fills 95 spaces efficiently. Adding retatrutide doesn’t create new spaces; it creates congestion competing for the same 100 spaces. Total occupancy doesn’t exceed ~95%.

Why Might Someone Hypothesize Combination?

Retatrutide’s glucagon receptor is unique to retatrutide. A hypothetical combination strategy might attempt to “keep tirzepatide’s GLP-1/GIP” while “adding retatrutide’s glucagon receptor.” This reasoning is theoretically sound but practically flawed because:

Manufacturing reality: Tirzepatide (pure GLP-1/GIP agonist) + retatrutide (GLP-1/GIP/glucagon agonist) is simply retatrutide at higher concentration. No additional glucagon signaling is achieved.
Receptor saturation: GLP-1 and GIP receptors are saturated with either compound alone. Additional molecular addition provides no additional GLP-1/GIP signaling.
PK/PD complexity: Combining two long-acting compounds creates unpredictable pharmacokinetics. Neither manufacturer recommends combination, and no published studies support the approach.

The Only Scientifically Sound Combination

If a research hypothesis requires both dual-agonist (GLP-1/GIP) and triple-agonist (GLP-1/GIP/glucagon) mechanisms, the design would be:
– Sequential study: Subjects receive tirzepatide for phase 1, washout period, then retatrutide for phase 2 (or vice versa)
– Comparative crossover: Tirzepatide in Group A, retatrutide in Group B, with controlled variables
– Not simultaneous: Never combining both in a single dosing phase

Key Takeaway Box: Decision Framework

Choose Tirzepatide when:
– Budget constraints are primary
– Efficacy target is 18-22%
– Research focuses on dual GLP-1/GIP mechanism
– Population is large (cost efficiency matters)
– Timeline is 12-16 weeks (retatrutide’s advantage is marginal short-term)

Choose Retatrutide when:
– Maximum efficacy is research requirement
– Budget allows for premium compound pricing
– Study population is small (per-subject cost less critical)
– Mechanism includes hepatic lipid metabolism
– Research hypothesis specifically requires three-receptor agonism

Do not combine. The pharmacologic rationale is absent, and competing molecules for identical receptors provides no additive benefit.

Part 9: Current Research Landscape and Emerging Data

Tirzepatide: Established Track Record

As of 2026, tirzepatide has accumulated:
– 4+ years of published research data
– Multiple Phase 3 trials across different populations
– Real-world observational studies in research supply chains
– Mechanistic studies isolating GLP-1 vs. GIP contributions

Tirzepatide is the reference standard against which newer compounds are measured. New research programs comparing novel agonists typically use tirzepatide as the comparator arm.

Retatrutide: Emerging Research

Retatrutide’s research portfolio includes:
– Jastreboff Phase 2 NEJM 2023 (PMID 37366315) — the primary peer-reviewed efficacy publication to date
– TRIUMPH program Phase 3 trials (TRIUMPH-4 protocol published DOM Jan 2026, PMID 41090431) — ongoing; efficacy readouts pending
– Cardiovascular outcomes program (TRIUMPH-CVD design announced; results pending)
– Limited real-world observational data (research stage)

Retatrutide is in active development phase. Long-term safety data (3+ years) remains limited. Research programs using retatrutide should budget for enhanced safety monitoring and regulatory reporting obligations, and should anchor protocol designs on the Phase 2 evidence base while Phase 3 results are pending.

Future Direction: Fourth-Generation Agonists

Published research pipeline shows multiple in-development compounds targeting:
– Quadruple agonists (GLP-1/GIP/glucagon/GCG-like peptide-1 receptor 2)
– Selective glucagon receptor agonists (glucagon benefit without GLP-1)
– Bispecific antibodies against multiple receptors simultaneously

The tirzepatide vs. retatrutide comparison will become historical within 3-5 years as newer mechanisms enter research availability. Current compound selection should account for this inevitable evolution.

Practical Research Checklist: Before Selection

Before committing to either compound, research programs should confirm:

Study Population:
– [ ] Baseline efficacy requirement determined (is ~20.9% Phase 3 tirzepatide sufficient, or is Phase 2 retatrutide ~24.2% needed — knowing Phase 3 retatrutide is still pending?)
– [ ] Budget for premium compound vs. standard compound established
– [ ] Population size and timeline finalized (larger/longer favors tirzepatide economics)

Mechanism:
– [ ] Research hypothesis specifically requires GLP-1/GIP only, or benefits from glucagon receptor?
– [ ] Hepatic lipid metabolism is outcome variable? (Favors retatrutide)
– [ ] Dual vs. triple agonism is mechanism of interest?

Regulatory and Safety:
– [ ] Enhanced safety monitoring capacity exists (especially for retatrutide, newer compound)
– [ ] Baseline screening protocols established
– [ ] Pancreatitis, GI, and rare adverse event definitions operationalized

Timeline and Data:
– [ ] Study duration ≥12 weeks (16 weeks preferred for plateau assessment)
– [ ] Publication strategy considers retatrutide as emerging compound (longer literature trail exists for tirzepatide)
– [ ] Regulatory pathway for research supply confirmed

Conclusion: The Phase 2 vs Phase 3 Comparison Question

Cross-phase, retatrutide Phase 2 outperforms tirzepatide Phase 3 by ~3 percentage points in published efficacy trials. This gap is:
– Real in Phase 2: Statistically significant in the Jastreboff 2023 trial
– Mechanistically predicted: Triple agonism should outperform dual agonism
– Modest in magnitude: Additional efficacy gain of ~2–3 kg for typical subjects
– Premium-priced: 15–35% higher compound cost typical
– Pending Phase 3 confirmation: TRIUMPH-4 Phase 3 readout will replace this cross-phase comparison with a definitive same-phase one

The question for research programs is not just “which is better?” but “is the emerging Phase 2 advantage worth the cost and pre-Phase-3 evidence uncertainty for my specific research goals?”

For budget-constrained, population-level efficacy studies, tirzepatide’s ~20.9% Phase 3 efficacy with established safety profile and lower cost remains the rational choice. For research requiring maximum metabolic perturbation or triple-receptor pharmacology as the mechanism variable, retatrutide’s Phase 2 ~24.2% efficacy may justify the premium and monitoring requirements — but the choice should be informed by the awareness that Phase 3 retatrutide outcomes are not yet peer-reviewed.

Neither compound is universally superior. Research program needs determine the optimal choice.

Common Questions

Q: Which compound produces more weight loss?
Retatrutide Phase 2 (Jastreboff 2023, PMID 37366315) produced ~24.2% mean reduction at 48 weeks at the 12 mg dose versus tirzepatide Phase 3 (SURMOUNT-1) ~20.9% at 72 weeks. The retatrutide Phase 2 effect is larger and faster, but the comparison is cross-phase — Phase 3 retatrutide (TRIUMPH-4) outcomes are pending publication. Treat the magnitude as suggestive, not definitive.

Q: Why does retatrutide have higher GI burden?
Adding glucagon-receptor activation amplifies GI motility effects. Published trial data shows ~47% retatrutide nausea incidence vs ~37% for tirzepatide, with retatrutide GI symptoms also taking longer to resolve.

Q: For pure mechanism research, which is the better tool?
Choose by the pathway under study. Isolating GLP-1/GIP synergy → tirzepatide. Investigating glucagon-receptor contribution to weight loss → retatrutide. Comparative pharmacology → both, plus monotherapy controls.

Q: Are there quality differences between tirzepatide and retatrutide supply chains?
Yes. Retatrutide had a documented 2025–2026 quality crisis with ~47% failure rates in independent re-testing. Tirzepatide has a longer market history with more reference data. Both require third-party HPLC + MS verification. See retatrutide quality crisis.

Q: What about cagrilintide or CagriSema in this comparison?
Cagrilintide is amylin-pathway — mechanistically orthogonal to both tirzepatide and retatrutide. CagriSema (cagrilintide + semaglutide) is a different combination strategy. Compare these in the Complete Weight-Loss Peptides Guide.

Q: How long should a comparative protocol run?
Minimum 24 weeks to capture both acceleration and plateau phases. Most published trials run 48–72 weeks. Shorter protocols cannot distinguish dual- vs triple-agonism differences reliably.

Tirzepatide — research-grade dual-agonist
Retatrutide — independently re-tested triple-agonist
Cagrilintide — amylin-pathway research compound

References and Further Reading

Verified PMIDs / DOIs for SURMOUNT-1, TRIUMPH-4, and the receptor pharmacology literature are consolidated in Product Catalog/MASTER_RESEARCH_CITATIONS.md. Researchers should pull canonical references from there or directly via PubMed.

SURMOUNT-1 — NEJM 2022 (DOI: 10.1056/NEJMoa2206038), tirzepatide phase 3.
Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. NEJM 2023. PMID: 37366315 (verified).
TRIUMPH-4 Phase 3 protocol — Diabetes Obesity & Metabolism Jan 2026, PMID 41090431. Phase 3 efficacy results pending.
Reviews of GLP-1 / GIP / glucagon receptor agonism in Nature Metabolism and Current Opinion in Endocrinology (2024–2026 issues).
GI safety meta-analyses spanning GLP-1 family compounds.

This article represents published research literature as of May 2026. Research compounds are for investigational use only. Artemis Labs supplies research-grade materials to qualified research institutions. Always consult current published literature and regulatory guidance before research design. For research purposes only. Not for human consumption. These statements have not been evaluated by the FDA.

Last updated: May 20, 2026.